Results: Five trials with 5,252 patients were ultimately included. Random-effects summary odds ratios (OR) were constructed using M-L heterogeneity model. Methods: We did a comprehensive search in electronic databases from inception through July 2020 for randomized-controlled trials, using the keywords “sodium-glucose cotransporter-2 inhibitor”, “dapagliflozin”, “heart failure”, “cardiovascular outcomes”, “major adverse cardiovascular events”, “all-cause mortality”, and “cardiovascular death”.
Recently, some studies have reported the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors in reducing the rates of hospitalization or urgent visits, resulting in IV therapy for heart failure in patients with type 2 diabetes mellitus (T2DM).
Miaobo Zhai †, Xin Du †, Changmei Liu and Huipu Xu *
0 kommentar(er)
